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ABSTRACT 
 
Over the past two decades, not only treatment options, but also the diagnosis, staging, and risk 
assessment of multiple myeloma (MM), have undergone significant development, partially due to a 
deeper understanding of MM pathogenesis. Conventional cytogenetics and fluorescence in situ 
hybridization are routinely assessed in MM, and when combined with ISS stage may attain an even 
better predictive potential. In order to achieve even more effective and individualized therapies, one 
crucial goal is the identification of genes and gene combinations that predict for response or 
resistance to chemotherapy. High-dose chemotherapy with autologous stem cell transplant (SCT) 
still remains the standard therapy for younger patients, with novel agents now being included in 
both pre-transplant regimens and post-transplant consolidation/maintenance approaches. Similarly, 
novel agents are also being incorporated into allogeneic SCT for selected patients. In the treatment 
of elderly patients with MM, novel agents have been successfully incorporated into less intensive 
regimens, including melphalan/prednisone, low-dose dexamethasone, and 
cyclophosphamide/dexamethasone. While second-generation proteasome inhibitors are currently 
being intensively investigated, the subcutaneous administration of bortezomib, being equivalent to 
the established i.v. route, is now entering clinical practice. Supportive care remains a crucial aspect 
in the management of MM. The European Myeloma Network Trialist Group aims to address these 
contemporary aspects in MM. 
 
 
Introduction to the European Myeloma Network Trialist Group and 
the 3rd Trialist Forum 
 
 
The European Myeloma Network (EMN), founded in 2005, represents an international cooperative 
network, including members of the GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto), 
HOVON (Hemato Oncology Foundation for Adults in The Netherlands), DSMM (Deutsche 
Studiengruppe Multiples Myelom), and other international study groups, for the diagnosis and 
treatment of multiple myeloma (MM). As in previous years, an international meeting of the EMN 
Trialist Group (TG) was held in Baveno, Italy, on 16–17 May 2010. This article summarizes the 
activities of the EMN-TG and the 3rd Trialist Forum, with most of the relevant aspects discussed at 
this meeting. 
 
 
 
 
Phase III protocols for younger patients with multiple myeloma 
 
 
  
Michele Cavo, Pieter Sonneveld, Benedetto Bruno  
 
High-dose therapy with autologous stem cell transplant (ASCT) is still considered the standard 
treatment approach for younger patients with MM (18–65 years, as well as up to 75 years with good 
performance status in clinical trials). The impact of different pre-transplant regimens including 
novel agents on stem cell mobilization, response, and survival in patients undergoing ASCT is 
being intensively investigated [1,2]. Results from phase II/III studies including novel agents in the 
induction treatment have shown an increase in complete remission/very good partial remission 
(CR/VGPR) rates not only pre- but also post-ASCT. However, non-transplant approaches with 
novel agent-based induction and ASCT performed at the time of relapse are currently also being 
evaluated. Questions that still remain to be answered are the role of ASCT versus novel agents, 
tandem versus single ASCT, and novel agent maintenance versus non-maintenance approaches. 
One innovative GIMEMA protocol presented at the meeting consists of induction therapy with 
three cycles of bortezomib, cyclophosphamide, and dexamethasone (VCD) followed by 
cyclophosphamide-induced stem cell mobilization and first randomization to either four cycles of 
bortezomib, melphalan, and prednisone (VMP) or MEL200 (melphalan 200 mg/m
2
) followed by 
single or tandem ASCT, with plans to present the preliminary findings at the American Society of 
Hematology (ASH) Meeting later this year [3]. After VMP or MEL200, patients will undergo a 
second randomization to receive consolidation with bortezomib, lenalidomide, and dexamethasone 
(VRD) versus no consolidation. The presence of cytogenetic abnormalities, such as deletion of 
chromosome 1p [del(1p)], amplification of chromosome 1q [ampl(1q)], translocation of 
chromosomes 4 and 14 [t(4;14)], 14 and 16 [t(14;16)], and 11 and 14 [t(11;14)], amplification of 
chromosome 9, and the deletion of chromosome 17p [del(17p)] as detected by fluorescence in situ 
hybridization (FISH) and deletion of chromosome 13 by conventional cytogenetics (CG) are 
assessed at diagnosis. Furthermore, immunophenotyping at diagnosis, during treatment, and at 
follow-up to enable the confirmation of a stringent complete remission (sCR) is incorporated in the 
protocol, and translational studies such as gene expression profiling (GEP) on purified MM plasma 
cells (PCs) and single nucleotide polymorphism (SNP) analysis for loss of heterozygosity (LOH) 
are also planned to potentially inform individualized treatment approaches in future trials. 
 
 
Phase II salvage protocols 
 
   
Jose A. Perez-Simon, Henk Lokhorst, Benedetto Bruno  
 
Allogeneic stem cell transplant (allo-SCT) appears to be a potentially curative strategy in MM, and 
is currently pursued worldwide within clinical trials. Novel agents, such as bortezomib, 
thalidomide, and lenalidomide, are being incorporated into induction regimens prior to allo-SCT in 
an attempt to increase the extent of cytoreduction before SCT, as well as in post-transplant 
consolidation or maintenance regimens to enhance anti-MM and graft-versus-myeloma effects. 
Since last year's EMN-TG meeting at Stresa, prospective transplant protocols have been designed to 
further evaluate the role of new drugs as induction before allo-SCT, and their toxicity, tolerability, 
and efficacy for maintenance when used as treatment after allo-SCT [4]. 
The phase II HOVON 76 study has examined the efficacy and safety of maintenance using 10 mg 
lenalidomide for 21 days each month, starting between 1 and 6 months after non-myeloablative 
(RIC) allo-SCT. Common toxicities were hematologic side effects and exacerbation of acute graft-
versus-host disease (GvHD) that only 58% of patients could continue lenalidomide beyond the 
fourth cycle [5]. Thus, future allo-SCT strategies may include increased conditioning intensity 
regimens within RIC protocols, improvement in GvHD and relapse prevention strategies, and 
combination approaches to capture both, e.g. combined rapamycin and bortezomib use, for both 
GvHD prophylaxis and MM maintenance treatment. 
 
 
EMN phase II melphalan chemoprediction trial 
 
Hans E. Johnsen, Martin Boegsted  
 
The main cause of treatment failure in malignant diseases, and in particular in MM, is the 
acquisition of resistance to anti-cancer agents in tumor cells. Understanding the mechanisms 
leading to multidrug resistance (MDR) is important for the development of even more effective and 
individualized therapies in MM. Moreover, the identification of genes or gene combinations 
responsible for drug resistance may be helpful to predict response versus resistance to 
chemotherapy in patients with MM. 
The working hypothesis of this EMN translational study has been that the combination of drug 
screens of B-lineage cancer cell lines and gene expression profiles (GEPs) can establish a genetic 
model for predicting drug resistance in patients with MM, which can be clinically validated in 
newly diagnosed candidates for high-dose melphalan and ASCT. The specific aims of the study are 
(1) to compare drug screens for melphalan of the NCI60 and B-cell lines, (2) to use a multivariate 
regression technique to develop a melphalan treatment predictor, and (3) to validate this predictor 
retrospectively in available clinical data sets from Arkansas Cancer Center ASCT-treated patients 
receiving ‘total therapy.’ To date the present study has established a melphalan resistance index 
based on genes involved in cancer and MM pathogenesis that may predict outcome following high-
dose melphalan. The impact of the generated gene list will be prospectively validated and correlated 
to known biomarkers in independent data sets, as planned in an upcoming prospective EMN 
intergroup trial. 
 
 
Phase III protocols for elderly patients with multiple myeloma 
 
Orhan Sezer, Sara Bringhen, Christian Straka  
 
Reduced high-dose melphalan (100–140 mg/m2) and ASCT is an option for elderly patients up to 
the age of 75 years. Patients not eligible for ASCT have historically been treated with the 
combination of melphalan and prednisone (MP) alone, and more recently in combination with novel 
drugs. Current trials have shown that the combination of chemotherapy and novel agents 
significantly improves therapeutic efficacy, with additive or synergistic activity in vivo. Therefore, 
several studies have investigated the addition of novel agents to the traditional MP regimen. 
Lenalidomide has been evaluated in combination with MP, with low-dose dexamethasone (Rd), and 
with cyclophosphamide/prednisone in untreated symptomatic patients with MM. For symptomatic 
patients aged 65–75 years, Rd with or without intensification by high-dose melphalan followed by 
ASCT may also be an effective therapeutic option. Dose-reduced tandem-ASCT (MEL140) with a 
novel induction (Rd) is therefore being tested against Rd without ASCT (e.g. DSMM XIII trial), 
and results are awaited with anticipation. Current trials also aim to decipher the role of melphalan 
versus cyclophosphamide, testing their ideal doses in combination with novel agents compared to 
alkylating-free novel drug combinations (e.g. Rd) in elderly patients. 
 
 
 
 
 
Phase II induction protocols 
 
 
 
 
 
Antonio Palumbo  
 
Subcutaneous (s.c.) administration of bortezomib seems equivalent to the established intravenous 
(i.v.) route, and may represent a convenient alternative for newly diagnosed elderly patients with 
MM. Subcutaneous bortezomib is also currently being tested in different combinations such as 
melphalan and prednisone (MP), cyclophosphamide and prednisone, and prednisone alone, 
followed by maintenance s.c. bortezomib until disease progression. Recent studies have also 
focused on the development of novel proteasome inhibitors such as NPI-0052, which induces 
apoptosis in MM cell lines and primary cells from patients with MM in vitro, has been shown to 
inhibit tumor cell growth in vivo, and is orally bioactive. 
 
 
Proposal for a substudy on the efficacy of intravenous ferric 
carboxymaltose in patients with functional iron deficiency 
 
Heinz Ludwig  
 
Anemia, defined as a hemoglobin level <12 g/dL (typically appearing as normochromic–
normocytic), is a frequent complication (50–70%) in patients with MM, and, as in other malignant 
diseases, can arise years before the diagnosis of MM [6]. In cancer patients in general and in 
particular in patients with MM, a low transferrin saturation (TSAT <20%) is a specific indicator of 
functional iron deficiency. At this meeting, the panel of experts emphasized the importance of 
determining (1) the prevalence of iron deficiency (ID) and (2) the efficacy of i.v. iron 
supplementation to correct ID in MM. The prevalence of ID, including absolute ID (AID) and 
functional ID (FID), has been investigated in a single center study including 1989 patients with 
various hematological and malignant diseases. Within the subgroup of patients with MM, ID and ID 
with anemia occurred in 44% and 21% of patients, respectively. Additionally, ID with and without 
anemia significantly increased with age, and was more frequent in patients older than 80 years than 
in those ≤60 years [7]. 
Recently, published data on the treatment of patients with chronic heart failure and ID, with or 
without anemia, with i.v. ferric carboxymaltose (FCM) suggest that currently available i.v. iron 
agents are effective in the management of ID and anemia, improving symptoms, functional 
capacity, and quality of life, while having an acceptable side-effect profile [8]. FCM might 
therefore be capable of correcting iron deficiency also in patients with MM, and should therefore be 
of interest to pursue further. 
 
 
Phase I network and protocols 
 
Martin Gramatzki  
 
Important considerations for performing phase I/II trials and their successful completion are well-
defined biological rationales to be tested in these studies. Well-designed treatment schedules and 
precise timing of these studies are important, amongst other aspects. Essential elements for the 
creation of a phase I network at each center include Good Clinical Practice (GCP)-trained 
personnel, adequate GCP-clinical trial facilities, intensive care access, basic interest in translational 
research, and sufficient numbers of patients to include in these studies. As these prerequisites are 
met by the EMN study group, the importance of organizing and implementing a phase I network 
with the creation of a platform for interested groups and the definition of a subcommittee for this 
purpose is being planned. 
 
 
Cytogenetics and biobanking for basic research: cytogenetics and 
biobanking protocols 
 
Alberto Rocci  
 
Conventional cytogenetics and FISH are routinely assessed prognostic markers in MM. A recently 
presented large multicenter analysis from the International Myeloma Working Group (IMWG) in 
9897 patients with MM evaluated the impact of CG and FISH, when combined with the 
International Staging System (ISS), on progression-free and overall survival (PFS and OS). The 
analysis revealed that t(4;14) most prominently correlated with diminished PFS. The combination 
of t(4;14) and ISS stage displayed a significantly increased predictive potential. For ISS stage I 
without t(4;14) as opposed to ISS stage III with concomitant presence of t(4;14), OS rates differed 
markedly at 4 years (81% and 22%, respectively). ISS stage I with t(11;14) revealed the best 
outcome, with an OS at 4 years of 89% [9]. 
Well-organized biobanking is therefore essential for basic and translational research. Samples such 
as whole bone marrow biopsies, purified CD138+ plasma cells, and serum from all patients enrolled 
in clinical trials should be collected at diagnosis and stored in reference laboratories. As 
proliferating cells are needed for conventional cytogenetic studies and these are not frequently 
obtained, FISH on purified PCs remains the ‘gold standard’ cytogenetic examination for MM. It 
appears that it is not essential to perform FISH analysis repeatedly (e.g. at relapse), unless this issue 
is being addressed in clinical trials, as FISH data have shown less variability with disease 
progression than initially thought. The recommended essential FISH panel should include t(4;14), 
t(14;16), and del(17p13) and optionally t(11;14), 1q gain, and 1p loss, while for conventional 
cytogenetics del(13q14) and aneuploidy can be determined. 
 
 
Future directions for basic research: common basic research 
projects 
 
Gareth Morgan  
 
The Dutch–German HOVON-65/GMMG (German-speaking Myeloma-Multicenter Group)-HD4 
trial has addressed the issue of whether genetic variation is associated with therapeutic outcome 
[10]. For this purpose, a molecular inversion probe (MIP) SNP chip was used, containing SNPs in 
genes responsible for cellular functions and pathways that may influence disease response, 
toxicities, complications, and survival. In this trial, patients were treated with three cycles of either 
vincristine, dexamethasone, and doxorubicin (VAD) or bortezomib, dexamethasone, and 
doxorubicin (PAD). Both treatment arms were compared in terms of response and possible SNP 
association. This analysis identified genetic polymorphisms uniquely associated with VAD or PAD 
treatment response. The establishment of central biobanks containing serum or plasma samples of 
homogeneously treated patients with MM is an important ongoing goal of clinical studies. 
 
 
 
 
MPT meta-analysis 
 
Anders Waage  
 
Several MPT trials have studied melphalan and prednisone (MP) versus the combination of MP and 
thalidomide (MPT) in transplant-ineligible elderly patients with MM. A meta-analysis integrating 
the existing outcome data related to the efficacy of MP versus MPT was also presented at the ASH 
2009 Annual Meeting [11]. Data of six currently available randomized controlled trials (RCTs) 
have all shown a significant improvement in overall response rate (ORR) with MPT. However, 
while an improvement in PFS was found in all of them, a significant improvement in OS has not 
been unequivocally observed. These six current trials comparing MP with MPT comprise a total of 
1685 patients, and have shown heterogeneity in terms of drug dosages administered, the number of 
cycles given, thalidomide maintenance versus no maintenance, and differences in patient selection. 
Despite these differences, the homogeneity seemed acceptable enough to perform a meaningful 
meta-analysis. For PFS and OS, data were extractable from four of the trials. MPT induced superior 
response rates compared with MP, and pooled hazard ratios for PFS and OS were 0.67 (0.55–0.8 
median 20.4 vs. 14.9 months; p = 0.001) and 0.82 (0.66–1.02; 39.3 vs. 32 months; p  = 0.085), 
respectively. Using the meta-analysis approach, MPT is confirmed to be superior to MP in terms of 
response and PFS, whereas an increased, but not significant, OS benefit is obtained. 
 
 
Conclusions 
 
Advances in the understanding of the pathogenesis of MM have led to the development of 
innovative targeted therapies, including the use of histone deacetylase inhibitors (HDAC inhibitors), 
heat-shock protein-90 (hsp-90) inhibitors, and second-generation proteasome inhibitors, such as 
carfilzomib [12] and NPI-0052, that can potentially be used either alone or in combination. When 
determining the most appropriate treatment doses and schedules for patients with MM, age and the 
presence of co-morbidities (cardiopulmonary disease, renal failure, polyneuropathy, diabetes 
mellitus, and possibly various other as yet undetermined organ function risks) all need to be 
considered. Additionally, age-adjusted therapy, and prevention and management of treatment- and 
MM-related adverse events, including supportive care measures, all need to be taken into account. 
Improvement in international cooperation, including the formation of the EMN-TG, represents a 
major achievement, and should lead to more substantial advances in the future management of MM. 
The ability to perform meta-analyses, such as that of the six randomized controlled trials comparing 
MP and MPT, which clearly show an improvement in response and PFS with MPT, combined with 
the fact that larger patient cohorts for meaningful clinical studies and translational research projects 
are being established, illustrate the need for future international efforts and consortiums which 
hopefully will contribute to further therapeutic gains for patients with MM. The next EMN-TG 
meeting has been scheduled for 15–16 May 2011. 
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